pipette
ENEnglish

Symptom variability and treatment response in pernicious anaemia: a longitudinal daily symptom tracking study

A. Thain, K. Hart, K. Burchell, P. Visser, K. R. Ahmadi

PreprintUso en el mundo real

En palabras de los autores

Pernicious Anaemia is an autoimmune-mediated disorder of vitamin B12 absorption, managed using fixed-interval vitamin B12 replacement regimens. Despite treatment, many patients report persistent or recurrent symptoms, suggesting substantial inter-individual variability in treatment response. More tailored approaches may therefore be needed to reduce symptom burden and improve quality of life. This prospective observational study used high-frequency longitudinal digital symptom monitoring to characterise symptom dynamics and heterogeneity in treatment response. UK adults with pernicious anaemia, recruited via the Pernicious Anaemia Society, self-reported daily symptoms (severity 0-10) and vitamin B12 treatments over three months. Analyses quantified within- and between-person variability, injection-aligned symptom response kinetics, and differences in treatment response by injection frequency. Sixty-eight participants were included in the longitudinal analyses, providing >5,100 person-days of symptom data over a mean of 76 days (SD 28). Most symptom variance was attributable to stable between-person differences (ICC range, 0.58-0.80), indicating the persistence of individual symptom phenotypes. Vitamin B12 injections were followed by rapid symptom improvement, although magnitude and timing varied markedly by symptom domain. Seventy-one percent of participants were classified as responders for composite symptom burden (median 4.65 to 2.36; p<0.001), while 29% showed no meaningful multisystem improvement (3.59 to 3.58; p=0.63). Cognitive symptoms improved earliest, typically within 24-72 hours; fatigue and pain responses peaked at 3-5 days, and neuro-sensory symptoms at 4-6 days. Responses clustered within individuals, indicating distinct responder phenotypes. Overall symptom burden improved most among participants receiving monthly injections, whereas those injecting weekly or more often had higher pre-injection burden and smaller improvements. These findings suggest that fixed-interval vitamin B12 replacement may not adequately reflect individual variation in symptom recurrence and treatment response. High-frequency digital symptom monitoring may provide a practical framework for characterising these patterns and for evaluating more individualised, symptom-guided vitamin B12 management.

Resultado principalEl resumen no menciona limitaciones.

Apareció: jueves, 5 de noviembre. medRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.11.03.26367157